10-Q: Allogene Therapeutics Reports Second Quarter 2024 Financial Results, Advances Pipeline

Allogene Therapeutics reports a net loss of $66.4 million for the second quarter of 2024, while focusing on key clinical programs and expanding its licensed territory.

Summary

• Allogene Therapeutics, a clinical-stage immuno-oncology company, announced its financial results for the second quarter of 2024, reporting a net loss of $66.4 million, compared to a net loss of $79.2 million for the same period in 2023.
• The company's research and development expenses decreased to $50.4 million in Q2 2024 from $62.0 million in Q2 2023, primarily due to reduced personnel costs.
• General and administrative expenses also saw a decrease, falling to $16.1 million from $18.5 million in the same period last year.
• Allogene reported a long-lived asset impairment charge of $5.0 million due to a decision to sublease one of its buildings.
• The company's cash and cash equivalents and investments totaled $444.6 million as of June 30, 2024.
• Allogene expects its cash runway to fund operations into 2026.
• The company completed a registered offering in May 2024, raising net proceeds of $105.2 million.
• Allogene is prioritizing four core programs, including cema-cel for large B-cell lymphoma and chronic lymphocytic leukemia, ALLO-316 for renal cell carcinoma, and ALLO-329 for autoimmune diseases.
• The company initiated a pivotal Phase 2 clinical trial (ALPHA3) for cema-cel as a first-line treatment for newly diagnosed LBCL patients with minimal residual disease.
• Allogene expanded its licensed territory to include the European Union and the United Kingdom, increasing its market opportunity for CD19 products.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there are positive developments such as the expansion of licensed territories and the initiation of a pivotal trial, the company continues to incur significant losses and faces numerous risks. The sentiment is neutral to slightly negative due to the ongoing financial challenges and the inherent risks associated with clinical-stage biotechnology companies.

Positives

• The company's net loss decreased year-over-year, indicating improved financial performance.
• Research and development expenses were reduced, suggesting cost management efforts.
• The company's cash position remains strong, providing a runway into 2026.
• The expansion of the licensed territory significantly increases the market opportunity for Allogene's CD19 products.
• The initiation of the ALPHA3 trial represents a key milestone in the development of cema-cel.

Negatives

• The company reported a net loss of $66.4 million for the quarter.
• A $5.0 million impairment charge was recorded due to a decision to sublease a building.
• The company continues to incur significant operating losses and expects to do so for the foreseeable future.

Risks

• The company's ultimate success depends on the outcome of its research and development activities and its ability to commercialize its product candidates.
• The company recognizes the need to raise additional capital to fully implement its business plan, and if such financing is not available, the company may be required to delay the development of its product candidates.
• The company's product candidates are based on novel technologies, which makes it difficult to predict the time and cost of product candidate development and the likelihood of obtaining regulatory approval.
• The company's clinical trials may fail to demonstrate the safety and efficacy of any of its product candidates, which would prevent or delay regulatory approval and commercialization.
• The company may encounter substantial delays in its clinical trials, or may not be able to conduct its trials on the timelines it expects.
• The company may fail to successfully manufacture its product candidates, operate its own manufacturing facility, or obtain regulatory approval to utilize or commercialize from its manufacturing facility or at a contract development and manufacturing organization (CDMO), which could adversely affect its clinical trials and the commercial viability of its product candidates.
• The company faces significant competition from other biotechnology and pharmaceutical companies, and its operating results will suffer if it fails to compete effectively.
• The company is highly dependent on its key personnel, and if it is not successful in attracting and retaining highly qualified personnel, it may not be able to successfully implement its business strategy.
• The company's reduction in force undertaken to extend its cash runway and focus more of its capital resources on its prioritized research and development programs might not achieve its intended outcome.
• The company's engineered allogeneic T cell product candidates represent a novel approach to cancer treatment that creates significant challenges for the company.
• The company is heavily reliant on its partners for access to TALEN gene editing technology for the manufacturing and development of its oncology product candidates.
• Servier's discontinuation of its involvement in the development of CD19 Products and Servier's disputes with Cellectis, or future disputes with the company, may have adverse consequences.
• The company relies and will continue to rely on third parties to conduct its clinical trials, and if these third parties do not successfully carry out their contractual duties or meet expected deadlines, the company may not be able to obtain regulatory approval of or commercialize its product candidates.
• The company relies on T cells from healthy donors to manufacture its product candidates, and if it does not obtain an adequate supply of T cells from qualified donors, development of those product candidates, or commercialization, if approved, may be adversely impacted.
• The FDA, or comparable foreign authorities, may disagree with the company's regulatory plan and the company may fail to obtain regulatory approval of its CAR T cell product candidates.
• If the company, or its collaborators, are required by the FDA, or comparable foreign regulatory authorities, to obtain approval (or clearance, or certification) of a companion diagnostic device in connection with approval of one of its product candidates, and the company, or its collaborators, do not obtain, or face delays in obtaining, approval (or clearance, or certification) of a companion diagnostic device, the company will not be able to commercialize the product candidate, and its ability to generate revenue will be materially impaired.
• The company depends on intellectual property licensed from third parties and termination of any of these licenses could result in the loss of significant rights, which would harm its business.
• If the company's efforts to protect the proprietary nature of the intellectual property related to its technologies are not adequate, it may not be able to compete effectively in its market.
• The company has identified a material weakness in its internal control over financial reporting, which could continue to adversely affect its ability to report its results of operations and financial condition accurately and in a timely manner.

Future Outlook

Allogene expects its cash runway to fund operations into 2026 and plans to explore opportunities to partner with collaborators on product candidates across its pipeline.

Management Comments

• Management expects to incur additional losses in the future to fund its operations and conduct product research and development.
• Management recognizes the need to raise additional capital to fully implement its business plan.
• Management expects its research and development expenses and general and administrative expenses will continue to increase.

Industry Context

The announcement reflects the ongoing challenges and opportunities in the immuno-oncology field, particularly in the development of allogeneic CAR T-cell therapies. The expansion of licensed territories and the initiation of pivotal trials are consistent with the industry's focus on expanding market reach and advancing promising therapies.

Comparison to Industry Standards

• Allogene's focus on allogeneic CAR T-cell therapies positions it as a competitor to companies developing autologous CAR T-cell therapies, such as Gilead (Yescarta) and Novartis (Kymriah).
• The company's approach to off-the-shelf therapies aims to address the limitations of autologous therapies, such as manufacturing complexity and patient-specific variability.
• The initiation of the ALPHA3 trial in first-line LBCL patients with minimal residual disease is a strategic move to expand the potential market for cema-cel, similar to how other companies are exploring earlier lines of treatment for their therapies.
• The expansion of the licensed territory to include the European Union and the United Kingdom is a common strategy for biopharmaceutical companies seeking to maximize the commercial potential of their products, similar to how other companies have expanded their reach.
• The company's financial results, including the net loss and cash position, are typical for a clinical-stage biotechnology company, and the company's cash runway is comparable to other companies in the sector.

Related Party Transactions

• The company recognized less than $0.1 million of collaboration revenue from Allogene Overland PRC.
• The company recorded a gain of $1.1 million from the Organizational Restructuring of Overland Therapeutics.
• The company recorded $0.1 million and $0.2 million of rent expense related to a sublease with Bellco Capital LLC for the three and six months ended June 30, 2024, respectively.
• The costs incurred for services provided, bonus, and out-of-pocket expenses incurred under a consulting agreement with Bellco Capital LLC were $0.2 million and $0.4 million for the three and six months ended June 30, 2024, respectively.

Stakeholder Impact

• Shareholders face the risk of dilution from future equity offerings and potential loss of investment due to the company's ongoing losses and risks associated with clinical development.
• Employees may experience uncertainty due to the company's reduction in force and the potential for future changes in personnel.
• Patients may benefit from the development of new therapies, but also face risks associated with clinical trials and the potential for adverse side effects.
• Suppliers and creditors may be affected by the company's financial performance and its ability to meet its obligations.
• Customers may benefit from the development of new therapies, but also face risks associated with clinical trials and the potential for adverse side effects.

Next Steps

• Complete enrollment in the ALPHA3 trial in the first half of 2026.
• Conduct efficacy analyses for the ALPHA3 trial in 2026.
• Submit a biologics license application (BLA) for cema-cel in 2027.
• Release initial data from the Phase 1b cohort of the ALPHA2 trial in early 2025.
• Provide a data update from the TRAVERSE trial by year-end 2024.
• File an investigational new drug (IND) application for ALLO-329 in the first quarter of 2025.
• Initiate the Phase 1 trial with ALLO-329 in the first half of 2025.
• Achieve proof-of-concept for ALLO-329 by year-end 2025.

Key Dates

Keywords

Allogene Therapeutics, immuno-oncology, allogeneic T cell, CAR T therapy, cemacabtagene ansegedleucel, ALLO-316, ALLO-329, clinical trials, biopharmaceutical, cancer treatment, lymphoma, leukemia, autoimmune disease, renal cell carcinoma, financial results, regulatory approval, manufacturing, licensing, research and development